Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of BMS-986165 (Deucravacitinib) in Moderate-to-Severe Plaque Psoriasis
2022-502361-15-00Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, open-label, single-arm trial of deucravacitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Primary endpoint: Adverse events and serious adverse events. Started Dec 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2022-502361-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502361-15-00.